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1. Introduction
Trachoma is the leading infectious cause of preventable blindness in the world today and
occurs as mesoendemic, endemic, or hyperendemic disease. The distribution is primarily in
tropical developing countries of the world including North and sub-Saharan Africa, the
Middle East, and the Northern Indian subcontinent. The disease has also been reported in
Southeast Asia and specific regions of Central and South America, Australia, and the South
Pacific Islands. Of the more than 600 million people afflicted, approximately 150 million
have visual deficits, and 12 million are predicted to be blind by the year 2020.
2. Clinical features
2.1. Symptoms
In the absence of secondary infection, symptoms are minimal and include mild foreign body
sensation in the eyes, occasional lacrimation, slight stickiness of the lids and scanty mucoid
discharge. In the presence of secondary infection symptoms of acute mucopurulent conjunc‐
tivitis develop.
2.2. Signs
2.2.1. Conjunctival
1. Congestion of upper tarsal and forniceal conjunctiva
2. Conjunctival follicles of 0.2 to 2 mm in diameter and are commonly seen on upper tarsal
conjunctiva and fornix, but may also be present in the lower fornix, plica semilunaris
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and caruncle. Sometimes, follicles may be seen on the bulbar conjunctiva. Follicles are
formed due to the scattered aggregation of lymphocytes and other cells in the adenoid
layer. Central part of each follicle is made up of mononuclear histiocytes, few lympho‐
cytes and large multinucleated cells called Leber cells. The cortical part is made up of
zone of lymphocytes showing active proliferation. Blood vessels are present in the most
peripheral part. In later stages signs of necrosis are also seen.
3. Papillary hyperplasia: Papillae are reddish, flat topped raised areas which give red and
velvety appearance to the tarsal conjunctiva. Each papilla consists of central core of nu‐
merous dilated blood vessels surrounded by lymphocytes and covered by hypertrophic
epithelium.
4. Conjunctival scarring may be irregular, star-shaped or linear. Linear scar present in the
sulcus subtarsalis is called Arlt’s line.
5. Concretions may be formed due to accumulation of dead epithedial cells and inspissat‐
ed mucus in the depressions called glands of Henle.
2.2.2. Corneal
1. Superficial Keratitis may be present in the upper part.
2. Herbert follicles refer to typical follicles present in the limbal area. These are histologi‐
cally similar to conjunctival follicles.
3. Pannus which is an infilteration of the cornea associated with vascularization, can de‐
velop at any point along the limbal margin but is most pronounced at the superior lim‐
bal margin. The vessels are superficial and lie between epithelium and Bowman’s
membrane; and later on the Bowman’s membrane is destroyed.
Pannus may be progressive (infiltration of cornea is ahead of vascularization) or regressive
also termed pannus siecus (vessels extend a short distance beyond the area of infiltration).
4. Corneal ulcer may sometimes develop at the advantage of pannus. Such ulcers are usu‐
ally shallow which may become chronic and indolent.
5. Herbert pits are the oval or circular pitted scars, left after healing of Herbert follicles in
the limbal area.
6. Corneal opacity may be present in the upper part. It may even extend down and in‐
volve the papillary area. It is the end result of trachomatous corneal lesions.
2.3. Differential diagnosis
1. Presence of large multinucleated Leber cells and signs of necosis differentiate trachoma
follicles from Adenovirus follicles conjunctivitis.
The distribution of follicles in trachoma is mainly on upper palpebral conjunctiva and for‐
nix. Sometimes, follicles may be seen on the bulbar conjunctiva.
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The corneal involvement of the disease includes lymphoid follicle formation at the limbus.
This is a characteristic feature of trachoma and can lead to the development of Herbert's pit.
Associated signs such as papillae and pannus are characteristic of trachoma.
2. Trachoma with predominant papillae is differentiated from palpebral form of spring ca‐
tarrh as follows:
Papillae are large in size and usually there is typical cobble-stone arrangement in spring ca‐
tarrh.
The pH of tears is usually alkaline in spring catarrh, while in trachoma it is acidic.
Discharge is ropy in spring catarrh
The corneal involvement of the disease includes lymphoid follicle formation at the limbus.
This is a characteristic feature of trachoma and can lead to the development of Herbert's pit.
In trachoma, there may be associated follicles and pannus.
3. Sequelae of trachoma
1. Sequelae in the lids may be trichisis, entropion, tylosis (thickening of lid margin), ptosis,
madarosis and ankylophearon.
2. Conjunctival sequelae include concretions, pseudocyst, xerosis and symblepharon.
3. Corneal sequelae may be corneal opacity, ectasia, corneal xerosis and total corneal pan‐
nus (blinding sequelae).
4. Other sequelae may be chronic daccryocystitis, and chronic dacryoadenitis.
The only complication of trachoma is corneal ulcer and it occurs due to rubbing by concre‐
tions, or trichiasis with superimposed bacterial infection.
4. Classification
Trachoma has always been an important blinding disease under consideration of WHO and
thus many attempts have been to streamline its clinical profile. The latest classification sug‐
gested by WHO in 1987 with the acrimony FISTO is as follows:
1. TF: Trachomatous inflammation-follicular is the stage of active trachoma with predomi‐
nantly follicular inflammation. To diagnose this stage at least five or more follicles (each
0.5mm or more in diameter) must be present on the upper tarsal conjunctiva. Further,
the deep tarsal vessels should be visible through the follicles and papillae.
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2. TI: Trachomatous inflammation-intense is diagnosed when pronounced inflammatory
thickening of the upper tarsal conjunctiva obscures more than half of the normal deep
tarsal vessels.
3. TS: Trachomatous scarring is diagnosed by the presence of scarring in the tarsal con‐
junctiva. These scars are easily visible as white, bands or sheets (fibrosis) in the tarsal
conjunctiva.
4. TT: Trachomatous trichiasis is labeled when at least one eyelash rubs the eyeball. Evi‐
dence of recent removal of intured eyelashes should also be graded as trachomatous tri‐
chiasis.
5. CO: Corneal opacity is labeled when easily visible corneal opacity is present over the
pupil. This sign refers to corneal scarring that is so dense that at least part of pupil mar‐
gin is blurred when seen through the opacity. The definition is intended to detect cor‐
neal opacities that cause significant visual impairment (less than 6/18).
5. The causative organism Chlamydia trachomatis
5.1. Taxanomy
Chlamydial organisms were historically referred to as Bedsonia or Miyagawanella and were
initially thought to be protozoa. Because of their small size and the problems encountered
with propagation, they were subsequently thought to be viruses. In the 1960s they were clas‐
sified as bacteria because Chlamydia express proteins (e.g., lipopolysaccharides) that are
functionally analogous to other bacteria, divide by binary fission, are inhibited by antibacte‐
rial drugs, contain ribosomes, and are structurally and morphologically similar to gram-neg‐
ative bacteria. However, Chlamydia are only distantly related to other eubacterial orders
based on phylogenies of ribosomal ribonucleic acid (rRNA) gene sequences. Chlamydiae
comprise their own order, Chlamydiales; a single family, Chlamydiaceae; and one genus,
Chlamydia. The genus Chlamydia is comprised of four known species: C. trachomatis, C. psitta‐
ci, C. pneumoniae, and Chlamydia pecorum.
Chlamydia trachomatis is made up of three biologic variants or biovars: trachoma, lym‐
phogranuloma venereum (LGV), and the rodent biovar that includes the mouse pneumoni‐
tis (MoPn) and hamster strains. There is 87% to 99% deoxyribonucleic acid (DNA)
homology among the human strains and biovars of C. trachomatis but only 30% homology
for the rodent strains.
With the exception of the rodent strains, C. trachomatis is currently known to infect only hu‐
mans. The infections in humans include the conjunctiva and lower and upper genital tracts,
including the rectum and lymphatics that drain the perineum. These infections are caused
by the 19 currently recognized serologic variants or serovars (defined by monoclonal and
polyclonal antibodies that react to epitopes on the major outer membrane protein MOMP of
C. trachomatis.) of the trachoma and LGV biovars.
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 Figure 1. Top left: Trachomatous Inflammation - Follicular Presence of follicles on the flat surface of the upper tar‐
salconjunctiva.Top right: Trachomatous Inflammation - Intense With enlarged vascular papillae marked inflamma‐
tory thickening of the upper tarsal conjunctiva obscures the deep conjunctival vessels. Middle left: Trachomatous
Scarring The scar (white/yellow) lines form a ‘network’ of fibrous scarring in the tarsal conjunctiva.Middle right: Tra‐
chomatous Trichiasis There is evidence of one or more eyelashes rubbing on the eyeball.Bbottom: Corneal Opacity
The patient has significantly reduced vision due to corneal scarring.
Serotyping has distinguished these serovars  into different  serogroups or  classes:  B  class
(serovars  B,  Ba,  D,  Da,  E,  L2,  and  L2a),  intermediate  class  (serovars  F  and  G),  and  C
class (serovars A, C, H, I, Ia, J, Ja, K, Ka, L1, and L3). Serovars A through K and Ba, Da,
Ia,  Ja,  and  Ka  were  previously  referred  to  as  trachoma-inclusion  conjunctivitis  (TRIC)
strains.  Trachoma is  primarily  caused  by  serovars  A,  B,  Ba,  and C,  whereas  adult  and
neonatal inclusion conjunctivitis are caused by serovars B or Ba, D through K, Da, Ia, Ja,
Ka, L1, L2, L2a, and L3, which are the sexually transmitted strains of the organism. The
LGV  serovars  tend  to  cause  more  severe  disease  and  can  invade  regional  lymphatics,
whereas  the  non-LGV  serovars  are  currently  known  to  infect  epithelial  cells  at  ocular,
respiratory, rectal, and genital mucosal surfaces.
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Serotyping has been the most widely accepted technique for classifying C. trachomatis or‐
ganisms. However, within the last decade, a new technique has been developed based on
sequencing of ompA and is referred to as ompA genotyping. (ompA was previously called
omp1, but the nomenclature has changed to be consistent with that of other bacteria.) This
latter technique has been and continues to be invaluable for evaluating the molecular epi‐
demiology, disease pathogenesis, and transmission dynamics of chlamydiae for STD and
trachoma populations.
5.2. Chlamydia trachomatis development cycle
Chlamydia  trachomatis  are  obligate  intracellular  parasites  that  are  unable  to  synthesize
their own energy (ATP) and are completely dependent on their host for energy. It has a
unique  biphasic  developmental  cycle  not  found in  any  other  bacteria.  There  is  the  ele‐
mentary  body  (EB)  is  the  infectious  form (spore-like  particle)  that  posses  a  rigid  outer
membrane  that  bind  to  receptors  on  host  cells  and  initiate  infection.  and  the  reticulate
body  (RB),  which  is  the  metabolically  active  form.  Once  the  EB  comes  in  contact  with
susceptible epithelial cells,  it  attaches by divalent cations and polycations, using heparin
sulfate as a bridge between receptors on the EB and the cell surface. The EB is taken up
into  a  phagosome  by  receptor-mediated  endocytosis.  There  is  ineffectual  lysosomal  fu‐
sion with the endophagosome because of their rigid outer membrane, and hence intracel‐
lular survival is insured.
A vacuole encloses the elementary body and the bacterium is now a reticulate body. Reticu‐
late bodies obtain their energy by sending forth “straw-like” structures into the host cell cy‐
toplasm. It can then replicate itself through binary fission. After division, the reticulate body
becomes the elementary body. Anywhere from 100 to 1000 EBs can be produced per infected
cell. In many cases, the cell ruptures and dies releasing the infectious progeny, but the cell
can also extrude the inclusion body by a process of exocytosis and is released trough reverse
endocytosis
6. Diagnosis
6.1. Clinical
A presumptive diagnosis of trachoma can be made based on clinical features,  especially
in an area where trachoma is  considered to  be  present.  The following signs are  impor‐
tant indicators for trachoma, and at least two must be present in person diagnosed: folli‐
cles  in  the  upper  tarsal  conjunctiva,  limbal  follicles  or  their  sequelae,  Herbert's  pits,
typical  conjunctival  scarring,  and pannus.  These signs along with conjunctival  detection
of  C.  trachomatis  in  the  laboratory  confirm  the  presence  of  endemic  or  hyperendemic
trachoma in the respective area.
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6.2. Laboratory
6.2.1. Cytology
The conjunctiva is swabbed with a Dacron or cotton swab, and the smear is made by rolling
the swab over a clean glass slide. Alternatively, the swab can be placed in a special transport
media for the respective diagnostic test. Epithelial cells that are clearly separated and the
presence of PMNs, lymphocytes, plasma cells, or Leber cells (giant macrophages that con‐
tain phagocytosed material) can denote an adequate sampling of the conjunctiva. The de‐
gree of inflammation and bacterial superinfection can also be appreciated from these
smears. Thus, although not diagnostic for chlamydiae, these findings are suggestive of tra‐
choma. Giemsa stain is inexpensive, and the test is easy to perform, which makes it attrac‐
tive for developing countries where trachoma is endemic or hyperendemic. However, the
sensitivity is only about 60% and, thus, should not be used in areas of low endemicity. With
this stain, the inclusion body is visualized as a basophilic, stippled inclusion in contrast to
the dark blue to purple color of the cell. However, other entities can also stain similarly:
These include goblet cells, bacteria, keratin, nuclear extrusions, and eosinophilic granules.
Lugol's iodine stains the glycogen-containing inclusion of C. trachomatis. It imparts a dark
yellow-brown color to the inclusion but is infrequently used, because it is insensitive. Com‐
mercially available fluorescent [fluorescein isothiocyanate (FITC)] conjugated monoclonal
antibodies against the MOMP, which is species-specific for C. trachomatis, or the LPS, which
is genus-specific for Chlamydia, are used in this test. The EBs are stained an apple green col‐
or and are visualized as extracellular round dots. The sensitivity for this test is approximate‐
ly 80% to 90%.
6.2.2. Tissue culture
Although the intracellular inclusions of trachoma were first identified by Halberstaedter
and von Prowazek4 in 1907, the actual organisms were finally cultured in 1957 by using
chick embryos. Today, tissue culture has supplanted the use of eggs, which has made isola‐
tion of chlamydiae more widely available, although it is still only performed in specialized
reference laboratories. Tissue culture remains the gold standard for C. trachomatis identifi‐
cation but is not 100% sensitive, probably because of the difficulty in maintaining a cold
chain (4°C for no longer than 24 hours and then -70°C) from the field site to a specialized
reference lab where the culture will actually be performed. Also, because some viability is
lost on freezing and some of the trachoma serovars are more difficult to propagate, culture
requires technical expertise, can take 3 to 6 days for results, and is very expensive. Many dif‐
ferent cell lines are now available for culture, including HeLa and McCoy cells. Additional
passages in tissue culture can increase the positive rate but have other drawbacks, including
a delay in the reporting time of the results. Fluorescein-conjugated antibodies are used to
detect the inclusions in cell culture, which are visualized as intracytoplasmic ovoid, round,
or irregularly shaped inclusions. This stain imparts a fluorescing, apple green color to the
inclusion body that stands out against the dark red cells that have been counterstained with
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Evans blue. Peroxidase-conjugated monoclonal antibodies are also available for the detec‐
tion of chlamydial inclusion bodies.
6.2.3. Antigen detection
ELISA or enzyme immunoassay (EIA) commercial assays are available to detect chlamydiae,
but the sensitivity is only 70% to 85%. However, these assays can be cost effective compared
with other commercially available tests such as the DNA detection assays. These tests detect
the EB via polyclonal or monoclonal antibodies directed against the genus-specific chlamy‐
dial LPS. The antibodies are conjugated with an enzyme that reacts with a substrate to pro‐
duce a change in color that can be detected by a specific wavelength in a spectrophotometer.
One advantage is that a 96-well format can be used to process multiple samples at one time.
Less technical expertise is required than for the above-mentioned tests. Another advantage
is that the kits contain a confirmatory test.
6.2.4. DNA detection
The commercial LCR and PCR tests are the most recent assays to be developed for detecting
Chlamydia. Primers that are specific for the organism anneal to the complementary strand
of DNA after denaturation. This target DNA is usually the plasmid, which is only present in
C. trachomatis and C. psittaci species. LCR amplifies a signal that occurs when the primers
hybridize with the plasmid DNA. In PCR, the actual DNA is amplified after hybridization.
Both tests can be used in a 96-well format in which 92 to 94 samples can be assayed at one
time. Both products are detected by spectrophotometers that are set at specific wavelengths
for the particular assay. An advantage to the commercial PCR test is that an internal control
plate can be run in parallel with the chlamydial detection plate to identify which samples
have inhibitors. Those samples that contain inhibitors can then be run by in-house PCR as‐
says that employ a DNA purification protocol that removes the inhibitors.
Chlamydial DNA can also be detected by commercially available hybridization probes.
These also hybridize with complementary plasmid or ompA DNA. The sample is usually a
swab of the conjunctiva that has been applied to a special filter paper immediately after the
sample has been obtained from the patient. Occasionally, DNA is extracted from a swab that
has been placed in a special collection media and then is applied to a filter. In both cases, the
filter is what is probed. The advantage of this technique is that the filter paper that contains
the samples can be stored at room temperature under field conditions and transported back
to the lab at a convenient time, without the necessity of a cold chain. The sensitivity of the
probes is 70% to 90%.
6.2.5. Serology
There are two serologic tests for Chlamydia: the microimmunofluorescent (MIF) test and the
complement fixation (CF) test. However, neither is specific for the organism because patient
sera can cross react with different serovars and species and may represent current or previ‐
ous sexually transmitted infection as opposed to conjunctival infection. The highest antibod‐
Common Eye Infections238
ies detected in the assay, however, are usually found against the initial infecting serovar,
even on subsequent infection. This concept is referred to as original antigenic sin. Further‐
more, ocular chlamydial infections tend to be chronic and endemic. Thus, these assays can‐
not be used to diagnose active infection, although occasionally MIF has been used for
epidemiologic studies. They are also only available in reference laboratories.
The CF test is the older of the two and detects group-reactive antigen on C. psittaci and C.
trachomatis. This test can be used for diagnosing ocular infections resulting from LGV or C.
psittaci. The MIF test employs EBs representing C. trachomatis serovars and usually one or
two strains of C. pneumoniae and C. psittaci. Sera, tears, and other bodily fluids can be used
in this assay. The fluids are serially diluted and reacted against the EBs that have been ap‐
plied and fixed to a slide in groups of dots. A FITC conjugated antihuman IgM, IgG, IgA or
secretory IgA antibody is used as the secondary antibody to detect antigen-antibody bind‐
ing. The slides are screened under fluorescent microscopy for fluorescing EBs that repre‐
sents the respective serovar or species. Serum IgM and IgG antibodies appear around 2- to
3-weeks postinfection and persist for 4 to 8 weeks, although the IgG antibodies persist for
much longer. Occasionally, IgM titers can rise again with reinfection or relapse of infection.
Approximately 80% of children in trachoma endemic areas and 90% of adults with inclusion
conjunctivitis will have detectable MIF antibodies. About half of the population in trachoma
endemic areas will have both serum and tear antibodies, and the titers are directly propor‐
tional to the severity of disease and to the presence of chlamydial organisms in the conjunc‐
tiva. In one study in Tunisia, 80% of children with severe disease, 31% with moderate
disease, and 17% with mild disease had tear antibodies to chlamydiae. Although the highest
titers are usually against the infecting serovar in ocular infections, the MIF test can be used
only for a diagnosis of active infection in neonates not in older children or adults. Neonates
acquire IgG antibodies from their mothers, and when they develop conjunctivitis, these tit‐
ers usually do not change during the course of the ocular infection. Most infected neonates
do develop a small rise in serum IgM antibodies, usually less than 1:32, which persists for a
few weeks.
7. Predisposing factors
Children are considered the primary source of infection because they usually become easily
infected from close contacts during frequent play and within small, crowded households.
However, female caregivers can also serve as an important reservoir in which the infection
is passed to them and then back to their children. Thus, children younger than 10 years are
at greatest risk for infection and reinfection.
Young women of childbearing age and other female caregivers are reported to have infec‐
tion rates that range from 5% to 10%. These infections likely represent transmission within
the household from and to children. Adult women develop more severe disease and seque‐
lae than their male counterparts; repeat infection is considered an important factor in dis‐
ease progression to trichiasis.
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Other factors are low socioeconomic status, poor facial hygiene and lack of water. Flies have
historically been considered vectors for transmission in Africa. However, data from recent
studies do not support the theory. In one study, fluorescein was used to stain the secretions
in the eyes of children. Within 15 to 30 minutes, the legs and bodies of the flies were also
stained with fluorescein. Eye-seeking flies such as Musca sorbens have been shown to land
on the eyes of multiple children as was reported in a study in Africa, but it is not clear how
many infectious EBs can be carried on the flies, how long they are viable, and whether the
inoculum is sufficient to cause infection. In The Gambia, of 395 flies captured from the eyes
of C. trachomatis-infected children, only two were positive by PCR and could not be con‐
firmed. It is certainly possible that flies carry other bacteria from eye to eye, which might
promote inflammatory disease and trachoma. Indeed, in many trachoma endemic countries,
there are seasonal outbreaks of conjunctivitis resulting from multiple bacterial species in‐
cluding Haemophilus influenzae, Haemophilus aegyptius, Streptococcus pneumoniae, Neis‐
seria meningitidis, N. gonorrhoeae, and Moraxella spp. These infections may actually
precede periods of increased trachoma prevalence rates. In a study in Tunisia, moderate to
severe trachoma was found significantly more often among children with bacterial coinfec‐
tions. Furthermore, pathogenic and nonpathogenic bacteria commonly colonize children
who reside in trachoma areas. Coinfection of C. trachomatis with these bacteria may be one
mechanism that is important for promoting severe inflammation, which results in conjuncti‐
val scarring and corneal vascularization years later.
8. Management
Management of trachoma involve curative as well as control measures. The World Health
Assembly has resolved to eliminate blinding trachoma by the year 2020. To this, the Global
Alliance for the Elimination of Blinding Trachoma (GET2020) was formed in 1998. Control
activities focus on the implementation of the SAFE strategy, surgery for trichiasis, antibiotics
for infection, facial cleanliness (hygiene promotion) and environmental improvements, to re‐
duce transmission of the organism. Each of these components tackles the pathway to blind‐
ness at different stages.
8.1. Active trachoma
Antibiotics for treatment of active trachoma may be given locally or systematically, but topi‐
cal treatment is preferred because:It is cheaper, there is no risk of systemic side-effects, and
Local antibiotics are also effective against bacterial conjunctivitis which may be associated
with trachoma.
The following topical and systemic therapy regimes have been recommended:
1. Topical therapy regimes. It is best for individual cases. It consist of 1percent tetracycline
or 1 percent erythromycin eye ointment 4times a day for 6 weeks or 20 percent sulface‐
tamide eye drops three times a day along with 1 percent tetracycline eye ointment at
bed time for 6 weeks.
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2. Systemic therapy regimes. Tetracycline or erythromycin 250mg orally, four times a day
for 3-4 weeks or doxycycline 100mg orally twice daily for 3-4 weeks or single dose of
1gm azithromycin has also been reported to be equally effective in treating trachoma.
3. Combined topical and systemic therapy regime. It is preferred when the ocular infec‐
tion is severe (TI) or when there is associated genital infection. It includes: (i) 1 percent
tetracycline or erythromycin eye ointment 4times a day for 6 weeks, and (ii) tetracycline
or erythromycin 250mg orally 4 times a day for 2 weeks.
It is increasingly appreciated that there can be a major mismatch between the signs of active
trachoma and the detection of chlamydial infection (Relationship between clinical signs and
infection). This is a particular problem for control programmes in determining who should
be offered antibiotic treatment; if only those with signs of trachoma are given antibiotic,
many infected individuals with significant loads of infection would be left untreated. The
WHO currently recommends that mass community-wide treatment should be used.
1. Determine the district-level prevalence of TF in 1–9-year-old children
a. If this is 10% or more, conduct mass treatment with antibiotic throughout the district
b. If this is less than 10%, conduct assessment at the community level in areas of known
disease
2. If assessment at the community level is undertaken
a. in communities in which the prevalence of TF in 1–9-year-old children is 10% or more,
conduct mass treatment with antibiotic
b. in communities in which the prevalence of TF in 1–9-year-old children is 5% or more,
but less than 10%, targeted treatment should be considered
In communities in which the prevalence of TF in 1–9-year-old children is less than 5%, anti‐
biotic distribution is not recommended
8.2. The sequelae
1. Concretions should be removed with a hypodermic needle.
2. Trichiasis may be treated by epilation, electrolysis or cryolysis
3. Entropion should be corrected surgically.
4. Xerosis should be treated by artificial tears.
8.3. Prophylaxis
Since immunity is very poor and short lived, reinfections and recurrences are likely.
Thus following prophylactic measures may be helpful against reinfection of trachoma.
1. Hygienic measures:
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Transmission of trachoma is closely associated with personal hygiene and environmental
sanitation. Facial cleanliness and environmental improvements the F&E components of the
SAFE strategy are primarily targeting the transmission of C. trachomatis between individu‐
als. Numerous epidemiological studies have found an association between dirty faces and
active trachoma in children
Eye-seeking flies are a common feature of many trachoma endemic communities and have
long been considered a potential vector. Chlamydia trachomatis was found (by PCR) on 15%
of flies caught leaving faces of children in a study from Ethiopia.
Many trachoma control programmes actively advocate for general improvements in water
supply (for face washing) and sanitation (to suppress fly populations). This drive has fortu‐
nately coincided with the setting of the United Nations’ Millennium Development Goals
(MDG). The target for the seventh MDG is to halve the number of people without safe water
and basic sanitation by 2015
2. Early treatment of conjunctivitis:
Every case of conjunctivitis should be treated as early as possible to reduce transmission of
disease.
3. Blanket antibiotic therapy (intermittent treatment).
WHO has recommended this regime to be carried out in endemic areas to minimize the in‐
tensity and severity of trachoma. The regime is to apply 1 percent tetracycline eye ointment
twice daily for 5 days in a month for 6 months.
The future of trachoma control
In previously endemic countries in Europe and elsewhere, trachoma declined in the face of
general improvements in living conditions and health. Such changes are beginning to hap‐
pen in some parts of currently endemic countries. However, for many communities it may
take many decades for general improvements in living standards to happen and to have an
impact on trachoma. Therefore, it is necessary to pro-actively implement the SAFE strategy
as the best validated approach to control this blinding disease. The limited published data
on the impact of implementing the SAFE strategy indicate that even in some of the most
highly endemic regions, such as South Sudan, significant reductions in the prevalence of ac‐
tive disease can be achieved.
4. The development of an efficacious vaccine:
Vaccine for C. trachomatis that would prevent and resolve infection has been slow largely
because of the intracellular nature of Chlamydia and lack of ability to genetically transform
the organism. However, recent advances in the field have identified some requirements for
vaccine design. It is now generally accepted that MOMP, possibly with other antigens,
would be important for a vaccine. However, because of the diversity of MOMP sequences
that define different C. trachomatis strains, more than one MOMP would be required. The
immune response that must be induced comprises mucosal sIgA antibody and systemic an‐
tigen-specific CD 4 TH1 lymphocyte responses. Protection of mice against challenge with
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MoPn has been partially successful using vaccine strategies that include conformationally
intact MOMP, naked DNA constructs of ompA and intact, nonviable organisms carried by
dendritic cells.175 Other attempts at vaccination were less successful and included recombi‐
nant poliovirus or Salmonella expressing MOMP, denatured MOMP, or MOMP peptides
(summarized in Brunham176). It is likely that a composite vaccine that includes intact
MOMP, as well as naked DNA representing ompA from various strains, may be required to
stimulate appropriate B- and T-cell responses, respectively. It may also be that only a few
MOMP and ompA DNA strain sequences or only specific conserved sequences from MOMP
and ompA are required to elicit a protective immune response. The development of the ide‐
al vaccine remains a significant challenge.
9. Adult inclusion conjunctivitis
Chlamydia sexually transmitted diseases account for more than 500 million cases world‐
wide; but the exact prevalence of adult inclusion conjunctivitis is unknown because infec‐
tion is usually self-limited and does not always reach medical attention. The primary source
of infection is from cervicitis in females and urethritis in males. The spread is from “hand -to
genital tract -to eye” (during sexual activity). The incubation period is considered to be ap‐
proximately 5 to 19 days. Persons between the ages of 15 and 30 years are at highest risk for
adult inclusion conjunctivitis.
9.1. Clinical features
Symptoms include:
Foreign body sensation.
Mild photophobia and
Mucopurulent discharges from the eyes.
Signs are:
Conjunctival hyperaemia more marked in the fornices.
Acute follicular hypertrophy predominantly in the lower palpebral conjunctiva
Superficial keratitis in upper hemisphere of the cornea.
Superior micropannus may also occur.
Pre-auricular lymphadenopathy is common finding.
Clinical course: the course of the disease is benign; but often evolves into the chronic follicu‐
lar conjunctivitis.
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9.2. Differential diagnosis
Adults develop a follicular conjunctivitis that can be indistinguishable from that of tracho‐
ma. The follicles may be present on both the lower conjunctiva and upper tarsus. The onset
is usually acute with preauricular lymphadenopathy on the involved side and a serosangui‐
neous to mucopurulent discharge. After 2 weeks of infection, corneal involvement is more
prominent and includes keratitis, subepithelial opacities, and infiltrates that are marginal
and/or central. Occasionally there is mild scarring and corneal vascularization referred to as
micropannus, but these are late findings, usually among cases that have not been treated.
Otitis media is a common complication of chlamydial conjunctivitis. Although there can be
prompt resolution of the disease, In addition there can be a genital tract disease (which fail‐
ure to treat) resulting in the recurrence of the conjunctivitis.
Inclusion conjunctivitis is caused by serotypes D to K of Chlamydia tachomatis. The LGV
strains (L1, L2, and L3) of C. trachomatis are responsible for a much more severe ocular dis‐
ease referred to as Parinaud's oculoglandular syndrome. This syndrome is comprised of an
inflammatory conjunctival response with severe lymphadenopathy involving the preauricu‐
lar, cervical, and submandibular nodes. The LGV serovars are uncommon in developed
countries with few reports in the literature but are very common in tropical and subtropical
developing countries. Occasionally keratoconjunctivitis resulting from L2 has been reported
as a consequence of laboratory accidents.
9.3. Treatment
The best form of treatment for adult inclusion conjunctivitis is to prevent chlamydial sexual‐
ly transmitted diseases (STDs). Unfortunately, most chlamydial STDs are asymptomatic for
males (approximately 40%) and females (approximately 70%) and usually go undetected be‐
cause routine diagnostic screening for C. trachomatis is not performed. Thus, it is important
to recognize adult inclusion conjunctivitis that is caused by C. trachomatis and treat both the
ocular and genital tract disease. Because chlamydial STDs cannot be resolved by topical ocu‐
lar antibiotics, systemic therapy is recommended. Most cases infected with non-LGV sero‐
vars will respond to oral tetracycline250mg four times a day for 3-4 weeks;
Doxycycline100mg twice a day for 1-2 weeks or 200mg weekly for 3 weeks, or erythromycin
250mg four times a day for 3-4 weeks; when tetracycline is contraindicated as in pregnant
and lactating females.
For LGV, the best treatment regimen for inclusion conjunctivitis caused by C. psittaci and C.
pneumoniae is unknown, although 6 weeks of oral antibiotics has been successful in some
cases for complete eradication.
9.4. Prophylaxis
Patient’s sexual partner should be examined and treated.
Improvement in personal hygiene and regular chlorination of swimming pool decrease the
spread of disease.
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10. Neonatal inclusion conjunctivitis
Approximately 5% of pregnant women have C. trachomatis infection of the cervix.which if
left untreated has 50% chance of the infant developing conjunctivitis. Neonatal inclusion
conjunctivitis is more common (about 10 times) than conjunctivitis resulting from N. gonor‐
rhoeae. The incubation period for chlamydial conjunctivitis is 1 to 3 weeks. Earlier infection
can occur if there is evidence for rupture of membranes. If left untreated, the conjunctivitis
can persist for 3 to 12 months. C. trachomatis is the leading cause of pneumonitis within the
first 6 months of life. Rectal shedding of C. trachomatis does occur and is more common
among infants with pneumonia. Onset of shedding does not usually occur before 6 to 12
weeks of age and can be as late as 12 months.
10.1. Clinical features
Conjunctivitis in the neonate is characterized by swelling of lids, a purulent discharge, and
hyperemia. If without treatment, neonates are at risk for conjunctival scarring, keratitis, and
superficial vascularization of the cornea. In addition, these infants if up to 6 months of age
are at risk for pneumonitis.
10.2. Treatment
Treating pregnant women is effective in preventing infants from acquiring conjunctival in‐
fection, although retreatment may be necessary in high-risk populations. In infants, systemic
treatment is recommended for the fact that topical treatment of neonatal inclusion conjuncti‐
vitis does not eradicate nasopharyngeal carriage, which can result in pneumonia or recur‐
rent ocular infection. In addition, mothers should be treated for genital tract infection to
prevent recurrence of chlamydial conjunctivitis in the neonate.
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